The Synthetics, Part II: Designer Drugs on the Horizon
November 14, 2019
Daniela Zaborskis, PhD
Director of Operations and Senior Scientist, Acutis Diagnostics
Mumtaz Akhtar, MS
Senior Researcher, Acutis Diagnostics
Learning Objectives
At the end of this presentation, participants should be better able to:
• Describe the pharmacology of kratom and designer benzodiazepines.
• Review of the overdose potential of kratom and designer benzodiazepines amongst commonly abused substances.
• Review of the legal status of kratom and designer benzodiazepines in the United States.
• Describe the ease of access to kratom and designer benzodiazepines.
• Review of the current state of detection methodologies to detect kratom and designer benzodiazepines.
Available Credit
- 1.00 AANP
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Attendance